This Humble Food Extract Puts Bone Drugs to Shame
An ancient fermented food rivals — and in key respects outperforms — the pharmaceutical drugs sold for bone loss, and a growing body of human clinical evidence now backs up what the original animal data suggested.
Read and share the X thread dedicated to this article here.
Story at a Glance
A naturally occurring compound in fermented foods, genistein, has shown the ability to improve bone density and strength, matching or surpassing leading osteoporosis drugs in multiple studies.
Human clinical trials and a 2024 meta-analysis found that genistein significantly improves bone health in postmenopausal women, particularly at doses of 50 mg/day or higher.
Genistein supports bone formation while reducing bone breakdown, offering a mechanism distinct from many conventional osteoporosis treatments.
Unlike drugs such as Fosamax, Evista, and hormone replacement therapy—which carry risks including fractures, jaw necrosis, blood clots, stroke, and cancer—genistein has demonstrated a favorable safety profile in long-term studies.
The evidence suggests that a traditional food-derived compound may provide a safer, effective alternative for supporting bone health, despite receiving far less attention than patented pharmaceutical therapies.
When I first wrote about this subject 14 years ago on GreenMedInfo, the headline finding came from a single, striking animal study. A decade of additional research has only strengthened the thesis. What began as a provocative laboratory result in rats has matured into a credible, human-tested case that a soy-derived nutrient called genistein belongs in the conversation about bone health — not as a fringe alternative, but as an evidence-backed agent that, dose for dose, holds its own against the multi-billion-dollar osteoporosis drug franchise.
This is the expanded, more fully documented version of that argument.
The Study That Started It
The foundational finding was published in the British Journal of Pharmacology in 2008 by Bitto and colleagues. In an animal model of established postmenopausal osteoporosis — not merely prevention, but treatment of bone that had already deteriorated — researchers took 96 ovariectomized rats, waited six full months for osteoporosis to set in, and then randomized them across eight groups to receive genistein aglycone, alendronate (Fosamax), raloxifene (Evista), or ethinyl-estradiol, each at two dose levels, for 12 weeks (Bitto et al., Br J Pharmacol 2008).
The results were remarkable. Genistein at 10 mg/kg produced a greater increase in both bone mineral density (BMD) and bone mineral content than every one of the three drugs. Beyond density — the crude measure of how much bone is present — genistein also outperformed the drugs on the measures that actually matter for fracture prevention: it significantly increased breaking strength and bone quality, raised the bone-formation marker bone-alkaline phosphatase (b-ALP) and the protective protein osteoprotegerin (OPG), and reduced the resorption marker collagen C-telopeptide (CTX) and the bone-degrading signal sRANKL, all “compared with the other treatments at all dose levels” (Bitto et al., Br J Pharmacol 2008).
The authors’ conclusion was unambiguous: “The results strongly suggest that the genistein aglycone might be a new therapy for the management of postmenopausal osteoporosis in humans” (PubMed 18695641).
What makes this groundbreaking is the nature of the comparison. Genistein is a food derivative — a phytoestrogen found in fermented soy, red clover, kudzu, fava beans, and even coffee. The three drug classes it bested are evolutionarily novel chemicals (xenobiotics) carrying well-documented adverse effects. A nutrient your ancestors ate beat the patented molecules at their own game.
This Is No Longer Just a Rat Study — The Human Evidence Has Arrived
The most common — and fair — criticism of the original article was that its centerpiece was an animal study. That objection no longer holds. In the years since, genistein has been tested in humans in long-term, randomized, double-blind, placebo-controlled trials, the gold standard of clinical evidence.
The 24-month Marini trial. Researchers at three Italian university medical centers randomized 389 osteopenic postmenopausal women to either 54 mg/day of genistein aglycone or placebo (both arms received calcium and vitamin D) for two years. At 24 months, BMD had increased in the genistein group and decreased in the placebo group at both the lumbar spine and femoral neck. Genistein also lowered urinary markers of bone breakdown, raised bone-formation markers, and — critically — did not thicken the endometrium (Marini et al., Ann Intern Med 2007).
A three-year safety and efficacy follow-up. When the cohort was followed to 36 months, the BMD gains at the femoral neck and lumbar spine were even larger than at two years. Just as importantly for a compound with estrogen-like activity, genistein “did not significantly change mammographic breast density or endometrial thickness,” preserved BRCA1 and BRCA2 expression, and actually reduced sister chromatid exchange (a marker of genetic damage) versus placebo. The authors described “a promising safety profile with positive effects on bone formation” (Marini et al., J Clin Endocrinol Metab 2008).
Head-to-head against hormone replacement therapy. An earlier randomized, double-blind trial pitted genistein (54 mg/day) directly against conventional HRT (17β-estradiol plus norethisterone) in early postmenopausal women. Both genistein and HRT significantly increased BMD in the femur and lumbar spine versus placebo. But the two diverged on bone-formation markers: genistein raisedbone-specific alkaline phosphatase and osteocalcin (signs of new bone being built), whereas HRT lowered them (Morabito et al., J Bone Miner Res 2002). Genistein matched HRT’s density benefit while behaving more like a true bone-builder.
A post-hoc analysis in frank osteoporosis. Reanalyzing the Marini cohort, investigators isolated the 121 women who were genuinely osteoporotic (not just osteopenic) at baseline. In the genistein group, femoral-neck BMD climbed from 0.62 to 0.70 g/cm² over two years; in placebo it fell from 0.61 to 0.57. By the end, the prevalence of osteoporosis in the genistein group had dropped to 12%, while it was unchanged in placebo (Lasco/Marini et al., Nutrients 2017).
The meta-analytic verdict. A 2024 systematic review and meta-analysis of randomized controlled trials, published in Osteoporosis International, found that isoflavone interventions significantly improved BMD at the lumbar spine, femoral neck, and distal radius in postmenopausal women. Crucially, the benefit was strongest when the intervention lasted at least 12 months and contained at least 50 mg/day of genistein — almost exactly the dose used in the successful Italian trials (Zhang et al., Osteoporos Int 2024).
Genistein’s reach extends beyond the skeleton. In the same 389-woman cohort, two years of genistein improved glycemic control and several cardiovascular risk markers, lowering fibrinogen and showing “favorable effects” the authors believed “might play a preventive role in the development of coronary artery disease” (Squadrito et al., J Clin Endocrinol Metab 2007). Compare that to the cardiovascular harms documented for the drugs below.
Why It Works: Selective Estrogen Receptor Modulation, by a Food
Genistein structurally resembles 17β-estradiol, but it is no blunt hormonal hammer. It functions as a selective estrogen receptor modulator (SERM) — the same principle that the drug raloxifene was engineered to mimic, except genistein arrives pre-packaged in food.
The key is receptor selectivity. Genistein binds preferentially to estrogen receptor beta (ERβ), which is strongly expressed in bone — particularly trabecular bone — rather than to ERα, which dominates in breast and uterine tissue (Akhtar et al., J Clin Aesthet Dermatol review 2024). This lets genistein stimulate bone-building estrogen signaling while leaving — or even down-regulating — the proliferative estrogen signaling in breast tissue. Although its estrogenic activity is far weaker than estradiol’s, genistein binds the receptor for a longer duration, allowing meaningful benefit when the body’s own estrogen has fallen short. Paradoxically, this enables a plant estrogen to blunt the proliferative activity of excess estradiol and xenoestrogen exposures — the same protective logic seen with the lignans in flaxseed.
Mechanistically, genistein works on both sides of the bone-remodeling equation. It promotes osteoblast (bone-building) activity and inhibits osteoclast (bone-degrading) activity, shifting the critical RANKL/OPG ratio toward bone preservation — exactly what the Bitto study measured, and what the human follow-up confirmed when genistein lowered sRANKL and raised OPG in women (Marini et al., J Clin Endocrinol Metab 2008). Animal work has also tied genistein’s effect to restoration of parathyroid-hormone signaling (PTH/PTHR1), suggesting a mechanism that reaches beyond simple estrogen mimicry (Miao et al., Int J Mol Sci 2011).
A note on sourcing: non-fermented soy contains genistin, the inactive glycoside. Friendly gut bacteria — or the fermentation in cultured foods such as miso, tempeh, and natto — biotransform it into the active genistein. This is precisely why traditional Asian diets have long treated fermented soy as both food and medicine.
For Those Wary of Soy: The Chickpea Alternative
None of this requires anyone to embrace soy. Soy carries genuine, defensible concerns — it is one of the U.S. “Top 9” allergens, and it delivers one of the highest dietary isoflavone loads of any common food, on the order of 100–200 mg per 100 g in soy flour per the USDA Isoflavone Database. For a person eating fermented soy occasionally, that load is a feature. But for someone taking a daily product over years, a high, fixed phytoestrogen dose is a design choice with real consequences worth weighing.
This is precisely the reasoning behind why we built our CardioNK fermented natto on chickpeas rather than soy, as I detailed in Why We Built Our Fermented Natto on Chickpeas and Not Soy. The substrate is not a side note — it is the architecture of the product. Chickpea fermentation produces highernattokinase activity than soy under matched conditions (~356 FU/g, roughly 22% above cracked soybean), supports robust vitamin K2 (MK-7) biosynthesis, and generates about 72% less of the sticky γ-PGA byproducttied to natto’s allergenicity and purification headaches — all while sitting outside soy’s allergen class entirely.
Crucially for the bone story told here, choosing chickpea does not mean abandoning the genistein pathway. Chickpea’s isoflavone profile is dominated by biochanin A and formononetin rather than free genistein — and biochanin A is the direct metabolic precursor the body demethylates into genistein. So chickpea delivers genistein’s benefits along a gentler, more gradual route, at a substantially lower total phytoestrogen load than soy. Biochanin A is no bystander, either: in the same ovariectomized-rat model used throughout this article, biochanin A prevented bone loss as effectively as 17β-estradiol — increasing osteoblast activity, suppressing osteoclasts, and lowering the RANKL/OPG ratio — but without the uterine stimulation estradiol caused (Su et al., Evid Based Complement Alternat Med 2013).
The takeaway is liberating rather than restrictive: the bone-protective phytoestrogen pathway is not soy-exclusive. Fermented chickpea offers a lower-allergen, lower-isoflavone-load way to feed the same biochanin-A-to-genistein machinery — which is why we made it the foundation of CardioNK.
Now Look at the Drugs
The true value of the comparison becomes clear when the drugs are examined honestly.
Alendronate (Fosamax) and the bisphosphonates
Alendronate is the franchise leader, and its mechanism is to poison osteoclasts so that old bone is no longer cleared. Over years, this can leave bone denser on a scan but more brittle in reality. The most alarming consequence is atypical femoral fracture — the thigh bone snapping under ordinary load. The risk rises with duration of use, climbing to roughly 100 per 100,000 patient-years after five to eight years of continuous therapy (Cureus 2025 review; Cleveland Clinic J Med 2018). A drug sold to prevent fractures can, with long use, cause a particularly devastating kind of fracture.
Bisphosphonates are also linked to osteonecrosis of the jaw — literally dying, exposed jawbone — a complication serious enough that the FDA-approved Fosamax label and Medication Guide warn of “severe jaw bone problems (osteonecrosis)” and “unusual thigh bone fractures” (FDA Fosamax Medication Guide; FDA Fosamax label). The risk of jaw osteonecrosis rises substantially after three years of oral use (Junquera et al., Med Oral Patol Oral Cir Bucal 2013). Add to this the drug’s notorious capacity to ulcerate the esophagus and stomach — the reason patients are instructed to swallow it with water and remain upright for half an hour — and the risk-benefit math looks very different than the marketing suggests.
Raloxifene (Evista)
Raloxifene is a synthetic SERM — a laboratory attempt to do what genistein does naturally. Its track record includes serious vascular harms. In the large RUTH trial of over 10,000 women, raloxifene significantly increased both venous thromboembolism (blood clots) and fatal strokecompared with placebo (American College of Cardiology, RUTH summary). A pooled analysis of the MORE and RUTH trials confirmed a higher incidence of fatal strokes and venous thromboembolic events on raloxifene, with the excess fatal-stroke risk emerging after three years (Barrett-Connor et al., Stroke 2009). The drug’s own risk profile concentrates the danger in women already at elevated stroke risk (Framingham-based analysis, 2009).
Estradiol and conventional HRT
Pharmaceutical hormone replacement carries the most famous cautionary tale in modern medicine. The Women’s Health Initiative estrogen-plus-progestin trial was halted early when investigators found that long-term use raised the risk of breast cancer by 26%, stroke by 41%, and heart attacks by 29%, and doubled the rate of venous thromboembolism (CMAJ 2002; WHI long-term review, Semin Reprod Med 2014). Estradiol is produced naturally in the body, but at the supraphysiologic, unopposed, or poorly metabolized levels created by pharmaceutical HRT, it can become cardiotoxic and carcinogenic.
Learn more about the under-reported dangers of common osteoporosis drugs on the GreenMedInfo database.
In the Interest of Honesty: The Mixed Evidence
A strengthened thesis is one that confronts its weak points rather than hiding them. The genistein-and-bone literature is not unanimous, and readers deserve the full picture.
Not every soy-isoflavone trial succeeded. Of the long-duration human studies, the Italian genistein trials by Marini and colleagues showed dramatic bone benefits, but three other multi-year trials — the U.S. studies by Levis and Alekel and the Taiwanese study by Tai — found little skeletal benefit from soy isoflavones (reviewed in Lappe et al., Eur J Nutr 2013). A handful of animal studies likewise reported genistein performing worse than estradiol or raloxifene on certain bone-strength measures (Filipović et al., Acta Biochim Pol 2009).
Several factors explain the divergence — and most of them actually sharpen the case for genistein done right:
Dose matters. The 2024 meta-analysis found benefit specifically when interventions delivered at least 50 mg/day of genistein (Osteoporos Int 2024). The successful Italian trials used 54 mg/day of purifiedgenistein aglycone; the null trials often used lower doses or mixed soy-isoflavone extracts.
Form matters. Genistein follows a biphasic, dose-dependent curve in animal studies — low-to-moderate doses build bone while excessive doses can blunt the effect — and the active aglycone differs from the inactive glycoside found in unfermented soy (Yang et al., Acta Pharmacol Sin 2011).
Duration matters. Benefit consistently required 12 months or more of supplementation (Osteoporos Int 2024).
In short, the failures tend to cluster around the wrong dose, the wrong form, or too little time — not around a fundamental failure of the molecule. When genistein aglycone is given at an effective dose for long enough, the human BMD signal is consistent and statistically robust.
The Osteoporosis Myth: When Denser Bones Aren’t Better Bones
There is another layer to this story that is rarely discussed: the assumption that increasing bone mineral density (BMD) necessarily translates into healthier, more fracture-resistant bones.
This assumption underlies much of modern osteoporosis treatment, yet it is increasingly difficult to defend scientifically.
Bone is not concrete. It is living tissue. Its strength depends not only on mineral content, but also on architecture, elasticity, collagen integrity, microvascular supply, and continuous remodeling. A bone can become denser while simultaneously becoming more brittle.
This distinction helps explain one of the most troubling paradoxes in osteoporosis medicine: drugs such as bisphosphonates can increase BMD on a DEXA scan while also increasing the risk of atypical femoral fractures after long-term use. By suppressing osteoclast activity, these drugs reduce the natural turnover process through which old, damaged bone is removed and replaced. The result can be a skeleton that appears stronger on paper while becoming less resilient in reality.
In other words, a denser bone is not necessarily a better bone.
I explored this issue extensively in a previous investigation, The Osteoporosis Myth: The Dangers of High Bone Mineral Density, where I reviewed evidence showing that excessively mineralized bone may lose flexibility and become more susceptible to fracture under certain conditions. This helps explain why some individuals with relatively modest BMD experience few fractures, while others with apparently normal or elevated BMD suffer catastrophic skeletal injuries.
Viewed through this lens, the findings on genistein become even more intriguing. Unlike therapies that primarily suppress bone turnover, genistein appears to support a healthier balance between bone formation and bone resorption, improving not merely density but multiple markers associated with bone quality and structural integrity. The distinction is critical. The ultimate goal is not to produce denser bones. It is to produce stronger, more resilient bones capable of adapting to the stresses of life.
The question we should be asking is not simply, “Does this increase bone density?” but rather, “Does this improve the quality of bone itself?”
The Bigger Picture
Two truths sit at the heart of this story.
First, foods and food extracts cannot be patented. A 54 mg/day dose of a soy nutrient that matches or beats blockbuster drugs threatens a lucrative franchise, which is precisely why genistein has never received the hundreds of millions of dollars in funding that a definitive, fracture-endpoint, head-to-head human trial would require. The researchers behind the most encouraging studies say so plainly, calling for “a large, well designed, and appropriately focused randomized clinical trial” (Nutrients 2017) — a trial that the economics of drug development make unlikely to ever materialize.
Second, age-related bone loss has been aggressively over-medicalized. The reflexive prescription of bisphosphonates for “osteopenia” — a statistical category, not a disease — exposes millions of women to atypical fractures and jaw necrosis in pursuit of a denser scan that does not always mean a stronger bone.
The evidence assembled here does not claim genistein is a miracle, but given its extensively researched profile, it should be considered more seriously for nutritional support. [view the over 250 conditions researchers have been exploring].
This article makes a narrower, sturdier claim: a humble, ancient, fermentable food extract has, in rigorous laboratory and human studies, demonstrated bone benefits that rival the pharmaceutical standard of care — without the strokes, the clots, the cancers, the jaw necrosis, or the brittle thigh bones. That a nutrient eaten for thousands of years can do this should not be surprising. It should be the starting point.
For hundreds of studies on natural approaches to osteoporosis, view the GreenMedInfo.com database on the subject.
Concerned about Soy? Fermented Chickpea is the Alternative
While much of the research on bone-supportive phytoestrogens focuses on soy-derived genistein, soy isn’t the only path. For those seeking a lower-allergen, regenerative-food alternative, fermented chickpea natto offers a compelling solution.
In the article below, I explore why we chose organically grown chickpeas from a regenerative farm using traditional cultivation methods as the foundation for our natto. Beyond providing vitamin K2 and high-potency nattokinase, fermented chickpeas contain biochanin A—a natural precursor to genistein—offering many of the same benefits through a gentler nutritional pathway.
Discover the remarkable nutritional, agricultural, and scientific rationale behind this next-generation fermented food:
Why We Built Our Fermented Natto on Chickpeas and Not Soy
The substrate is not a side note. It’s the story behind CardioNK.
Share the X thread dedicated to this post below:
Key References
Bitto A, et al. “Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.” Br J Pharmacol. 2008;155(6):896-905. PubMed 18695641
Marini H, et al. “Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial.” Ann Intern Med. 2007;146(12):839-47. PubMed 17577003
Marini H, et al. “Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study.” J Clin Endocrinol Metab.2008;93(12):4787-96. OUP / PubMed 18796517
Morabito N, et al. “Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women.” J Bone Miner Res.2002;17(10):1904-12. PubMed 12369794
Lasco A, Marini H, et al. “Antiosteoporotic activity of genistein aglycone in postmenopausal women: a post-hoc analysis.” Nutrients. 2017;9(2):179. PubMed 28241420
Systematic review/meta-analysis. “Isoflavone intervention and its impact on bone mineral density in postmenopausal women.” Osteoporos Int.2024;35(3):413-430. PubMed 37875614
Squadrito F, et al. “Effects of genistein on predictors of cardiovascular risk in osteopenic postmenopausal women.” J Clin Endocrinol Metab. 2007;92(8):3068. OUP
Atypical femoral fracture risk: Cureus 2025; Cleveland Clinic J Med 2018
FDA Fosamax (alendronate) label & Medication Guide: Label; Medication Guide
Raloxifene RUTH/MORE: ACC RUTH summary; Stroke 2009
Women’s Health Initiative: CMAJ 2002; Semin Reprod Med 2014
Mechanism / SERM / ERβ review: J Clin Aesthet Dermatol 2024; Int J Mol Sci 2011
Mixed/contradictory evidence: Eur J Nutr 2013; Acta Biochim Pol 2009; Acta Pharmacol Sin 2011
Biochanin A and bone: Su SJ, et al. “The preventive effect of biochanin A on bone loss in ovariectomized rats.” Evid Based Complement Alternat Med. 2013. PubMed 23533501
CardioNK substrate rationale: Ji S. “Why We Built Our Fermented Natto on Chickpeas and Not Soy.” Substack, 2026
All bone drugs are poisons. They have never helped my wife and even made some bones weaker. Big pharma can go to the devil and take the evil doctors that buy into this bone drug crap with them.
Excellent information! I refuse to get another DEXA scan because there is not point....I would not take any of the drugs that supposedly cure the problem (due to their bad effects). Is this available to buy somewhere, and if so, where? Thank you....I enjoy your articles!